Diagnostic News and Research

RSS

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.

8 Mar 2010

Improvements needed in communicating cancer recurrence risks and treatment decisions with patients

A new study has found that one in three early-stage breast cancer patients who received genomic testing when deciding about treatment options felt they did not fully understand their discussions with physicians about their test results and their risk of recurrence. About one in four experienced distress when receiving their test results.

8 Mar 2010

Scientists devise software algorithm to detect medically useful information from whole-blood samples

Scientists at the Stanford University School of Medicine have devised a software algorithm that could enable a common laboratory device to virtually separate a whole-blood sample into its different cell types and detect medically important gene-activity changes specific to any one of those cell types.

8 Mar 2010

Engineers built sensor array that can detect single molecules of hydrogen peroxide

MIT chemical engineers have built a sensor array that, for the first time, can detect single molecules of hydrogen peroxide emanating from a single living cell.

7 Mar 2010

Healthy communication between patients and physicians reduces medical errors

National Patient Safety Awareness Week is taking place from March 7th to the 13th. This year’s theme is all about healthy communication between patients and their physicians. The simple theme Let’s Talk: Healthy Conversations for Safer Healthcare is aimed at helping people become more involved in their own health care.

6 Mar 2010

Differentiation of cirrhosis from inflammation in patients with ALD: Novel bedside criteria identified

Alcoholic liver disease (ALD) is the most common cause of liver cirrhosis in the Western world. Liver biopsy is currently considered the gold standard for assessing hepatic fibrosis or cirrhosis in these patients. However, it is an invasive procedure, with rare but potentially life-threatening complications and its accuracy is limited due to sampling error. Transient elastography (FibroScan-, FS) is a novel rapid and noninvasive method to assess liver fibrosis via measurement of liver stiffness (LS).

6 Mar 2010

Legislation requires hospitals to disclose prices in Wisconsin

The Milwaukee Journal Sentinel: "The frustration of finding out what hospitals and doctors charge for common services -- from routine office visits to diagnostic tests and surgical procedures -- could soon get a lot easier in Wisconsin. The state Senate and Assembly have passed legislation that will require hospitals to disclose average prices for the 75 most common inpatient services and 75 most common outpatient services based on their contracts with commercial health plans.

6 Mar 2010

It Starts with the Heart: Community initiative launched to support not-for-profits of all sizes

Health Diagnostic Laboratory Inc., www.hdlabinc.com, has launched a community initiative known as It Starts with the Heart, a company-wide commitment to support not-for-profits of all sizes in making a difference in their community.

6 Mar 2010

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

In an announcement today, Humanetics Corporation reported that its BIO 300 medical radiation countermeasure drug candidate has been issued a U.S. patent. The patent is assigned to the United States of America with Humanetics as the designated licensee.

5 Mar 2010

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

MicroPhage announced that it has submitted human data from a pivotal clinical study of its ‘Microphage MRSA/MSSA Blood Culture Test’ to support a U.S. Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage’s instrument-free, rapid tests is based on the Company’s patented Bacteriophage Amplification platform technology. MicroPhage further announced that it has already begun OUS commercial shipments of the test.

5 Mar 2010

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Saladax Biomedical, Inc. announced today the close of an $8.4 million Series C Preferred offering led by Excel Venture Management of Boston. Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors. The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

5 Mar 2010

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Predictive Biosciences today announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium, being held March 5-7 in San Francisco.

5 Mar 2010

Health Discovery delivers letter of gratitude and support to Congressman Edolphus Towns for holding congressional hearing

Health Discovery Corporation announced today that it delivered a letter of gratitude and support to Congressman Edolphus Towns, Chairman of the House Committee on Oversight and Government Reform for holding today, March 4, 2010, a congressional hearing on “Prostate Cancer: New Questions About Screening and Treatment.”

5 Mar 2010

Combating liver fluke: Queen's University Belfast heads international research effort

Queen's University Belfast is spearheading a £1 million international research effort to combat liver fluke - a parasite which causes disease in livestock, resulting in billions of pounds in losses every year to farmers around the world.

5 Mar 2010

Quest Diagnostics, Surescripts announce agreement to pioneer integrated service to improve clinical outcomes

Two of the nation's largest healthcare information networks, Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Surescripts®, The Nation's E-Prescription Network™, today announced an agreement to pioneer the formation of an integrated service to make laboratory and prescription information broadly and easily accessible to physicians.

From Quest Diagnostics 5 Mar 2010

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

According to estimates from the American Cancer Society, melanoma, the most serious form of skin cancer, was responsible for an estimated 8,650 deaths in the United States in 2009. Of growing concern among dermatologists is the fact that melanoma is now the most common form of cancer for young adults 25-29 years old and the second most common cancer in adolescents and young adults 15-29 years old.

5 Mar 2010

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.

5 Mar 2010

Diamedix and Delta Biologicals’ suite of diagnostic tests: Fumouze Diagnostics to be exclusive distributor in France

IVAX Diagnostics, Inc., a fully integrated global in vitro diagnostics company, announced that Diamedix Corporation has signed a distribution agreement with Fumouze Diagnostics, a division of Sofibel S.A.S., of Paris, France, pursuant to which Fumouze Diagnostics will be the exclusive third party distributor of Diamedix Corporation and Delta Biologicals S.r.l.’s suite of diagnostic tests in France. Diamedix is a U.S. subsidiary of IVAX Diagnostics and Delta Biologicals is IVAX Diagnostics’ subsidiary located in Italy. The initial term of the distribution agreement is three years.

5 Mar 2010

BioClinica announces partnerships with Health Sciences International and PRL Central Laboratory Services

BioClinica™, Inc.,, a global provider of clinical trial management services, today announced it has created strategic partnerships with two clinical research organizations (CROs), Health Sciences International, Inc., and PRL Central Laboratory Services. Both alliances strengthen the BioClinica Certified Partner Program, a group of VIP CRO partners chosen based on therapeutic expertise and customer satisfaction.

From Clario 5 Mar 2010

Positron announces the sale of Attrius PET scanner to Ochsner Health System of Louisiana

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, announced the sale of its AttriusTM PET scanner to Ochsner Health System of Louisiana.

5 Mar 2010

Diagnostic News and Research

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Improvements needed in communicating cancer recurrence risks and treatment decisions with patients

Scientists devise software algorithm to detect medically useful information from whole-blood samples

Engineers built sensor array that can detect single molecules of hydrogen peroxide

Healthy communication between patients and physicians reduces medical errors

Differentiation of cirrhosis from inflammation in patients with ALD: Novel bedside criteria identified

Legislation requires hospitals to disclose prices in Wisconsin

It Starts with the Heart: Community initiative launched to support not-for-profits of all sizes

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Health Discovery delivers letter of gratitude and support to Congressman Edolphus Towns for holding congressional hearing

Combating liver fluke: Queen's University Belfast heads international research effort

Quest Diagnostics, Surescripts announce agreement to pioneer integrated service to improve clinical outcomes

Latest diagnostic tools play crucial role in aiding dermatologists to spot melanomas at earlier

bioTheranostics launches CancerTYPE ID database and KRAS mutational testing

Diamedix and Delta Biologicals’ suite of diagnostic tests: Fumouze Diagnostics to be exclusive distributor in France

BioClinica announces partnerships with Health Sciences International and PRL Central Laboratory Services

Positron announces the sale of Attrius PET scanner to Ochsner Health System of Louisiana

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News